Introduction {#s0005}
============

Small-cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a highly lethal ovarian malignancy that occurs in young women (average age 24) ([@bb0005]). The early age of onset and familial aggregation of some cases suggest a hereditary cause ([@bb0005]). These undifferentiated cancers are comprised of small hyperchromatic cells with brisk mitotic activity, and can be difficult to distinguish morphologically from other undifferentiated tumors. Based on their microscopic appearance, SCCOHTs have been referred to as rhabdoid tumors, however, their cell of origin is unknown. Approximately 60% of SCCOHTs present with hypercalcemia and some have been shown to express parathyroid hormone-related protein ([@bb0005]). The primary ovarian tumors are almost always unilateral and roughly half are metastatic at diagnosis. Even among stage IA cases, five year survival is only 33% ([@bb0005]).

Our group and others recently reported that inherited and sporadic mutations in the *SMARCA4* gene, which encodes the BRG1 protein (a component of the SWI/SNF chromatin remodeling complex), are the major cause of SCCOHT ([@bb0010]). SCCOHT arising in *SMARCA4* mutation carriers does not express immunohistochemically detectable BRG1. It also has been shown that other members of the SWI/SNF family are frequently mutated in various types of cancers ([@bb0015]). Of relevance to SCCOHT, *SMARCA4*, or the related *SMARCB1* gene, are mutated in virtually all rhabdoid tumors, with germline mutations causing the disease in some of the cases ([@bb0020]). This report describes the first instance of genetic counseling and prophylactic bilateral oophorectomy based on mutational analysis of the *SMARCA4* gene in familial SCCOHT.

Case {#s0015}
====

This patient is a 33 year old Caucasian mother of three teenage boys. Three female relatives had previously been diagnosed with SCCOHT (ages 26, 24 and 12 years) and two had died of the disease ([@bb0010]). We recently reported identification of the causative *SMARCA4* mutation in the affected women in this family, c.2617-3 C \> T ([@bb0010]). This mutation results in a truncated protein that is subject to nonsense-mediated decay and was accompanied by a deleterious mutation in the other allele in the tumor. In view of the position of this patient in the pedigree and the known age distribution at diagnosis of SCCOHT (14 months to 47 years) ([@bb0005]), we offered her genetic testing, resulting in the identification of the known familial mutation. Prior to genetic testing, we discussed the possibility of prophylactic bilateral oophorectomy. We explained that the risk of SCCOHT for carriers of deleterious mutations in *SMARCA4* has not yet been well quantified, but the penetrance appears to be fairly high. We also noted the three cases of SCCOHT in this family, all confirmed by pathology report ([@bb0010]). The patient elected to undergo total laparoscopic hysterectomy and bilateral salpingo-oophorectomy, and the procedure was completed uneventfully. She received estrogen replacement therapy post-operatively. The ovaries were serially sectioned and examined by a gynecologic pathologist to look for evidence of premalignant or early malignant changes, but none were found. Immunohistochemical staining of multiple sections of both ovaries did not reveal loss of BRG1 expression in the ovarian stroma, follicles, or epithelium.

Discussion {#s0010}
==========

Current evidence suggests that inherited forms of SCCOHT may be more common than previously thought ([@bb0020]). Given the rarity of these tumors, expert pathology consultation is appropriate in verifying the diagnosis, which can be facilitated by demonstration of loss of BRG1 immunostaining in tumor nuclei. Although in many tumors both *SMARCA4* mutations are somatic, in some cases one mutation is germline and others in the family may also be carriers. In view of this, genetic counseling and mutational analysis of the *SMARCA4* gene should be offered to families affected by SCCOHT. Mutational analysis can be performed in academic centers and commercially and should be covered by insurance. The penetrance of germline mutations for SCCOHT is difficult to estimate, but appears to be considerable. Identification and counseling of male *SMARCA4* mutation carriers are also important, as their daughters may inherit the mutation. It is unclear whether germline *SMARCA4* mutations increase the risk of other types of cancers in women or men, but somatic mutations in this gene have been found in lung cancer, medulloblastoma and Burkitt lymphoma ([@bb0015]).

Most patients with SCCOHT present with a pelvic mass. In the absence of a known family history of the disease, unilateral oophorectomy is usually performed in those with stage I disease. A definitive diagnosis of SCCOHT is unlikely to be rendered on intraoperative frozen section and most of these cases occur well prior to the onset of menopause or completion of childbearing. If the final pathology report shows SCCOHT, immunostainining for BRG1 should be performed in the tumor. Germline genetic testing should be recommended if there is a loss of BRG1 expression ([Fig. 1](#f0005){ref-type="fig"}). Mutational analysis of the cancer and demonstration of a somatic mutation and loss of heterozygosity in the other allele may also be helpful to identify somatic *SMARCA4* mutations and will provide assurance that a germline mutation was not missed ([Fig. 1](#f0005){ref-type="fig"}). If the mutation is somatic, a second surgery to remove the other ovary is not needed in stage IA cases, as the contralateral ovary should not be at increased risk for SCCOHT. If a germline mutation is found, removal of the other ovary should be strongly considered.

It is instructive to compare the role of prophylactic surgery in *SMARCA4* carriers to its more established role in preventing high grade serous cancers of the ovary, fallopian tube and peritoneum in *BRCA1/2* mutation carriers. In view of the high lethality of serous cancers and lack of effective early detection methods, it is recommended that prophylactic bilateral salpingo-ophorectomy be performed after age 35, when the risk of high grade serous cancers begins to rise in carriers ([@bb0025]). In contrast, delaying prophylactic oophorectomy in those with stage I SCCOHT and in unaffected *SMARCA4* carriers until childbearing is complete seems risky in view of the young age of onset and high lethality of this disease. Although screening and early detection using imaging techniques might be an alternative prior to prophylactic bilateral oophorectomy, this may not reduce mortality from a cancer such as SCCOHT with its high propensity for metastasis. However, it is possible that these tumors, which arise as a mass in the ovary, may be easier to detect at an early stage using imaging than *BRCA1/2* associated cancers that primarily arise and spread from the fallopian tube epithelium. Since no cases of SCCOHT have been reported after age 45, it may be reasonable to perform preventive oophorectomy only opportunistically in older *SMARCA4* mutation carriers who are having surgery for other indications.

Careful gross and microscopic examination should be performed in prophylactically removed ovaries of *SMARCA4* carriers to look for a premalignant or malignant lesion. None were seen in this case, nor has this been reported in the literature ([@bb0005]), but this is the first prophylactic surgery reported for this disease and lesions may be found with additional experience. The cell of origin of SCCOHT is unknown, but these cancers clearly arise from the ovary, perhaps from some type of stem cell. The *SMARCA4* mutation carrier who underwent prophylactic surgery in this case report was 33 years old and was fortunate to not have already developed SCCOHT. Hopefully in the future, carriers will be identified at much earlier ages when prophylactic surgery can be performed while the prevention of SCCOHT is likely to be most effective. The degree to which very young unaffected carriers, particularly those who are prepubertal, can participate along with their parents in making this difficult decision will vary based on their age and maturity.

*SMARCA4* mutation carriers will increasingly be identified in childhood and early adolescence and should then be counseled about prophylactic oophorectomy, but many will not have chosen a partner or considered conception. Ovarian hyperstimulation and immediate in vitro fertilization are not realistic options in most circumstances. There has been substantial improvement in pregnancy rates using cryopreserved oocytes due to improved methods with vitrification that involve more rapid freezing ([@bb0030]). Because success rates are similar to those using conventional in vitro fertilization, oocyte cryopreservation is no longer considered experimental for medical indications such as cancer ([@bb0035]). This may represent the best approach for many of these patients. A *SMARCA4* mutation carrier who is not ready to conceive could undergo ovarian hyperstimulation and oocyte harvest prior to prophylactic bilateral oophorectomy with uterine preservation for future pregnancy via delayed in vitro fertilization. To prevent genetic transmission of the mutation, preimplantation genetic diagnosis of the first polar body prior to oocyte cryopreservation or of a subsequent embryo would be recommended ([@bb0040]). Since there are case reports of SCCOHT prior to puberty, prophylactic bilateral oophorectomy could conceivably be considered in some *SMARCA4* mutation carriers prior to menarche. In such cases, oocyte harvest and cryopreservation would not be feasible, but the uterus could be left in place for subsequent pregnancy using donor oocytes.

Although pregnancies have been reported after cryopreservation of ovarian tissue with subsequent reimplantation, the success rate is much lower and this is still considered experimental. An additional concern is that this could transplant cancer cells back into the patient. This is particularly problematic in SCCOHT, where the heightened cancer risk is specific to the ovary.
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